Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
Alto Neuroscience initiated a Phase 2b trial of ALTO-207 for treatment-resistant depression (TRD), aiming to replicate strong efficacy signals from the PAX-D study and prior Phase 2a data. The trial will enroll approximately 178 adults and uses a MADRS primary endpoint aligned with FDA standards, potentially supporting a single Phase 3 registrational pathway.
Key figures
- Drug Name
- ALTO-207
- Phase Of Trial
- Phase 2b
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.